Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders
Weihong Kuang,1,* Liantian Tian,2,* Lili Yue,1 Jin Li1 1Department of Psychiatry and Mental Health Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Occupational Respiratory Disease Research Center, No 4 West China Hospital/West China School of Public...
Guardado en:
Autores principales: | Kuang W, Tian L, Yue L, Li J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1193a496130b4cdd93d6524a39a124a1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017) -
Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
por: Jiang KD, et al.
Publicado: (2017) -
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
por: Wang G, et al.
Publicado: (2018) -
Preliminary Study on Changes of Sleep EEG Power and Plasma Melatonin in Male Patients With Major Depressive Disorder After 8 Weeks Treatment
por: Xue-Qin Wang, et al.
Publicado: (2021) -
Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton B, et al.
Publicado: (2018)